Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Bone Miner Res
Hlavní autoři: Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming‐Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916366/
https://ncbi.nlm.nih.gov/pubmed/31411768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.3848
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky